Track topics on Twitter Track topics that are important to you
* GSK announces regulatory submissions for subcutaneous formulation of Benlysta (Belimumab) for patients with systemic lupus disease
Original Article: BRIEF-GSK files regulatory submissions in U.S. and Europe for lupus drugNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...